CLAIMS

1. A stable pharmaceutical formulation of an α4β7 antibody comprising buffer, sugar and surfactant, wherein the concentration f sugar is less than 80 mg/ml.

2. The antibody formulation according to claim 1, wherein the formulation further comprises pharmaceutically acceptable excipients such as stabilizers selected from amino acids, salts, and combinations thereof.

3. A stable pharmaceutical formulation of α4β7 antibody comprising histidine-phosphate buffer, 60 mg/ml of sugar, free amino acid, salt and surfactant.

4. The antibody formulation according to claim 3, wherein the sugar is trehalose.

5. A stable pharmaceutical formulation of α4β7 antibody comprising phosphate buffer, at least 60 mg/ml of sugar, free amino acid, and surfactant, wherein the formulation is stable at 50 °C for two weeks and maintains at least 97 % of the monomeric content of the antibody under above mentioned storage conditions.

6. The α4β7 antibody formulation according to claim 4, maintains at least 55% of the antibody in the formulation as main peak when stored at 50 °C for two weeks.

7. The antibody formulation according to claim 3 or 5, wherein the free amino acid is arginine or lysine or glycine.

8. The antibody formulation according to claim 1 , 3 or 5, stabilizes the antibody at concentrations from about 50 mg/ml to 200 mg/ml.

9. The antibody formulation according claim 1, 3 or 5, is a liquid or lyophilized formulation.